ROCKLINC Investment Partners Inc. on Royalty Pharma plc
Thesis
ROCKLINC views Royalty Pharma as a high-quality financial toll collector on global pharmaceutical innovation rather than a traditional drug developer. It buys senior contractual claims on drug sales, normally after approval, avoiding much of the direct research, manufacturing and operating expense borne by pharmaceutical companies. The portfolio spans more than 35 approved therapies and almost 20 clinical candidates, with new products offsetting erosion from mature medicines. The manager highlights expenses historically below 7% of portfolio receipts, returns on equity above 20%, and strong conversion of receipts into investable cash. Shares at approximately 10 times earnings are regarded as inexpensive for this business model, while substantial repurchases increase free cash flow per share. ROCKLINC sees an exceptional margin of safety and durable long-term compounding.
“RPRX offers an exceptional margin of safety for long-term investors seeking compounding wealth protection and growth.”
Key risks
- Patent expirations and generic erosion can reduce royalty receipts from older drugs.
- Approximately 29% of revenue is tied to the Vertex cystic fibrosis franchise.
- Drug trial failures or unexpected safety problems can hurt individual royalty assets, even though the portfolio is diversified.
- Royalty pricing depends on accurately underwriting a medicine’s long-term commercial durability.